In Alzheimer’s disease (AD), deregulation of the MAPK/ERK and Nrf2-ARE pathways contributes to characteristic symptoms such as memory loss, synaptic dysfunction, and tau hyperphosphorylation [107]. This evidence concerns the gene NFE2L2 and early-onset autosomal dominant Alzheimer disease.